94.34
-2.10 (-2.18%)
| Previous Close | 96.44 |
| Open | 97.33 |
| Volume | 557,891 |
| Avg. Volume (3M) | 1,039,573 |
| Market Cap | 2,647,963,392 |
| Price / Sales | 8.40 |
| Price / Book | 11.11 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2025 - 2 May 2025 |
| Profit Margin | -17.12% |
| Operating Margin (TTM) | 10.98% |
| Diluted EPS (TTM) | -1.94 |
| Quarterly Revenue Growth (YOY) | 66.60% |
| Total Debt/Equity (MRQ) | 47.37% |
| Current Ratio (MRQ) | 3.61 |
| Operating Cash Flow (TTM) | -28.50 M |
| Levered Free Cash Flow (TTM) | 1.11 M |
| Return on Assets (TTM) | -3.20% |
| Return on Equity (TTM) | -22.10% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Mixed |
| Health Information Services (Global) | Bearish | Mixed | |
| Stock | GeneDx Holdings Corp. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | -1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -3.5 |
| Average | -1.90 |
|
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Growth |
| % Held by Insiders | 12.70% |
| % Held by Institutions | 86.29% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (TD Securities, 16.60%) | Buy |
| Median | 80.00 (-15.20%) | |
| Low | 78.00 (Wells Fargo, -17.32%) | Hold |
| Average | 87.00 (-7.78%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 75.80 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 09 May 2025 | 80.00 (-15.20%) | Buy | 67.23 |
| TD Securities | 01 May 2025 | 110.00 (16.60%) | Buy | 62.32 |
| Wells Fargo | 01 May 2025 | 78.00 (-17.32%) | Hold | 62.32 |
| Goldman Sachs | 19 Feb 2025 | 80.00 (-15.20%) | Hold | 111.31 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FEELEY KEVIN | 66.85 | - | 420 | 28,077 |
| Aggregate Net Quantity | 420 | |||
| Aggregate Net Value ($) | 28,077 | |||
| Aggregate Avg. Buy ($) | 66.85 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FEELEY KEVIN | Officer | 30 Apr 2025 | Acquired (+) | 420 | 66.85 | 28,077 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |